Recent Updates
Recently added Catalysts
RARE

Mereo BioPharma and Ultragenyx Present Data from the Phase 2b ASTEROID Study of UX143 (setrusumab) in Osteogenesis Imperfecta (OI) at the American Society for Bone and Mineral Research (ASBMR) 2021 Annual Meeting

Friday, October 1, 2021 1 min read
Key Takeaway: Mereo BioPharma and Ultragenyx Present Data from the Phase 2b ASTEROID Study of UX143 (setrusumab) in Osteogenesis Imperfecta (OI) at the American Society for Bone and Mineral Research (ASBMR) 2021 Annual Meeting

Full Press Release Details

Mereo BioPharma and Ultragenyx Present Data from the Phase 2b ASTEROID Study of UX143 (setrusumab) in Osteogenesis Imperfecta (OI) at the American Society for Bone and Mineral Research (ASBMR) 2021 Annual Meeting.
Tags: RARE Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Oct 1, 2021